Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

医学 指南 临床实习 重症监护医学 免疫疗法 内科学 肿瘤科 家庭医学 癌症 病理
作者
John B.A.G. Haanen,Michel Obéid,Lavinia Anne Spain,Franck Carbonnel,Yin-Shuang Wang,Caroline Robert,Alexander Richard Lyon,Wolfgang Wick,Marie Kostine,Solange Peters,Karin Jordan,James Larkin
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:33 (12): 1217-1238 被引量:1587
标识
DOI:10.1016/j.annonc.2022.10.001
摘要

OverviewAdverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs).irAEs are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Supplementary Table S1, available at https://doi.org/10. 1016/j.annonc.2022.10.001). 1 The aim of this European Society for Medical Oncology (ESMO) Clinical Practice Guideline (CPG) is to provide specific guidance on irAE management.Recommendations provided are based on evidence from the scientific literature, clinical experience and analogy to the treatment of autoimmune diseases (ADs), where appropriate.Consensus for the recommendations was obtained by direct communication, scientific debate and agreement.Further information regarding the provision of patient information, routine baseline screening before ICI initiation, monitoring during ICI therapy, management of outpatients versus inpatients and that of corticosteroid (CS)-refractory patients and patients with specific conditions can be found in Section 1 of the Supplementary Material, available at https://doi.org/10.1016/j.annonc.2022.10.001. General guidance for immunosuppressionirAE management generally consists of four sequential steps: (i) diagnosis and grading of irAEs, (ii) ruling out differential diagnoses and pre-immunosuppression work-up, (iii) selecting the appropriate immunosuppression strategy for grade !2 events and (iv) active evaluation at 72 h to adapt treatment.See Supplementary Table S2 and Section 1 of the Supplementary Material, available at https://doi.org/ 10.1016/j.annonc.2022.10.001.To minimise the occurrence of CS-induced AEs, the following general guidance is proposed 2 :The lowest effective CS dose should be prescribed for the shortest possible duration, which, in general will be several weeks for grade !3 irAEs, including tapering CS therapy tapering or discontinuation only on medical advice Lifestyle adaptations to minimise the risk of CS-induced AEs Immunosuppressive drugsOptimising the choice of immunosuppressive agents.Prospective studies evaluating the safety and efficacy of immunosuppressant agents in irAE management are
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Orange的应助被miss张采纳,获得10
1秒前
1秒前
1秒前
1秒前
samantha完成签到,获得积分10
1秒前
小巧紫蓝发布了新的文献求助10
1秒前
吕耀炜完成签到,获得积分10
1秒前
47发布了新的文献求助10
2秒前
布噜噜噜噜完成签到,获得积分10
2秒前
沿岸有贝壳完成签到,获得积分10
2秒前
秋风的应助被途中采纳,获得20
2秒前
江江发布了新的文献求助20
2秒前
小七完成签到,获得积分10
2秒前
尹雪儿发布了新的文献求助10
2秒前
2秒前
2秒前
Erin发布了新的文献求助10
3秒前
无霜完成签到,获得积分10
3秒前
3秒前
田様的应助被YPHCC采纳,获得30
3秒前
鱼欧完成签到,获得积分10
3秒前
4秒前
热爱发布了新的文献求助10
4秒前
不知道关注了科研通微信公众号
4秒前
yylkwdr完成签到,获得积分20
4秒前
zjj完成签到,获得积分10
4秒前
CipherSage的应助被畅快的秋蝶采纳,获得10
4秒前
Andreas发布了新的文献求助10
4秒前
Asioz完成签到 ,获得积分10
5秒前
SibetHu发布了新的文献求助10
5秒前
小笛子完成签到,获得积分10
5秒前
Jeff发布了新的文献求助10
5秒前
yj发布了新的文献求助10
5秒前
6秒前
cdercder的应助被君子之昔采纳,获得10
6秒前
万能图书馆的应助被lu采纳,获得10
6秒前
大力冰烟发布了新的文献求助10
7秒前
凶狠的梦之完成签到,获得积分10
7秒前
7秒前
崔泽发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175853
求助须知:如何正确求助?哪些是违规求助? 9567457
关于积分的说明 21792632
捐赠科研通 7770447
什么是DOI,文献DOI怎么找? 3431918
关于科研通互助平台的介绍 2556276
邀请新用户注册赠送积分活动 2477418